Lapatinib Plus Capecitabine in Women with HER-2–Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial

OBJECTIVES. A planned interim analysis of study EGF100151 prompted early termination of enrollment based on a longer time to progression with lapatinib and capecitabine than with capecitabine alone in patients with human epidermal growth factor receptor (HER)-2(+) previously treated advanced breast...

Descripción completa

Detalles Bibliográficos
Autores principales: Cameron, David, Casey, Michelle, Oliva, Cristina, Newstat, Beth, Imwalle, Bradley, Geyer, Charles E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2010
Materias:
Academia–Pharma Intersect
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228041/
https://www.ncbi.nlm.nih.gov/pubmed/20736298
http://dx.doi.org/10.1634/theoncologist.2009-0181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228041/
https://www.ncbi.nlm.nih.gov/pubmed/20736298
http://dx.doi.org/10.1634/theoncologist.2009-0181

Ejemplares similares